HK inno.N opens HK inno.N Square, Unveiling an Integrated R&D Hub
February 3, 2025
HK inno.N opens HK inno.N Square, Unveiling an Integrated R&D Hub
R&D workforce and facilities have been consolidated in one location, providing additional momentum for the development of new drug pipelines and growth engines… Ushering in a new era for Pangyo.
HK inno.N announced on Monday, February 3, the official opening of ‘HK inno.N Square’, an innovative platform for driving research and development (R&D), with 450 R&D personnel now gathered in Sujeong-gu, Seongnam-si, Gyeonggi-do.
HK inno.N Square provides an all-in-one R&D environment, spanning 10 floors above ground and 6 below, covering a total floor area of 40,785m² (12,338 pyeong) in Pangyo 2nd Techno Valley, Seongnam-si, Gyeonggi-do. The facility is designed to maximize collaboration among HK inno.N’s employees by bringing together its research institute workforce, previously located in Icheon, Gyeonggi-do, with other departments involved in R&D.
The first basement level includes a restaurant, fitness center, and an in-house library, while the ground floor features a café and daycare center. The remaining floors are designated for research labs, office spaces, and workspaces for small and medium-sized startups.
The design concept of HK inno.N Square draws inspiration from the natural world, aiming for seamless integration with its surroundings. The design embodies the dynamic spirit and growth potential of HK inno.N, as the company is poised to evolve into a global leader in the bio and healthcare sectors. The space fosters open communication, with minimal separation between different work areas, optimizing the use of space for enhanced operational efficiency.
Dalwon Kwak, CEO of HK inno.N, commented, “HK inno.N Square, a comprehensive and integrated space for R&D personnel and infrastructure, will serve as a new platform for advancing our own research and open innovation, facilitating quick and efficient communication.” He added, “We expect this new space to maximize the synergistic effects of R&D, contributing to the active discovery of new drug pipelines for chronic diseases and immune disorders, thus laying the foundation for our development into a global leader in the pharmaceutical and biotechnology industries.” (The End)